STOCK TITAN

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, has announced its participation in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for Thursday, October 17, 2024, at 2 p.m. ET. Neil F. McFarlane, President and CEO of Zevra, will represent the company at the panel.

The conference will be streamed live on M-Vest, with investors able to register and watch the discussion through the M-Vest page. For those unable to attend live, an archived version of the presentation will be made available in the 'Events & Presentations' section of Zevra's Investor Relations website at investors.zevra.com.

Zevra Therapeutics (NASDAQ: ZVRA), un'azienda che si occupa di terapie per malattie rare, ha annunciato la sua partecipazione a un Panel sulle Malattie Rare durante il Maxim Healthcare Virtual Summit 2024. L'evento, presentato da Maxim Group, è programmato per giovedì 17 ottobre 2024, alle 14:00 ET. Neil F. McFarlane, Presidente e CEO di Zevra, rappresenterà l'azienda nel panel.

La conferenza sarà trasmessa in diretta su M-Vest, con la possibilità per gli investitori di registrarsi e guardare la discussione attraverso la pagina di M-Vest. Per coloro che non possono assistere dal vivo, sarà disponibile una versione archiviata della presentazione nella sezione 'Eventi e Presentazioni' del sito web delle Relazioni con gli Investitori di Zevra all'indirizzo investors.zevra.com.

Zevra Therapeutics (NASDAQ: ZVRA), una empresa de terapias para enfermedades raras, ha anunciado su participación en un Panel de Enfermedades Raras en el 2024 Maxim Healthcare Virtual Summit. El evento, presentado por Maxim Group, está programado para jueves 17 de octubre de 2024, a las 2 p.m. ET. Neil F. McFarlane, Presidente y CEO de Zevra, representará a la empresa en el panel.

La conferencia se transmitirá en vivo a través de M-Vest, donde los inversores podrán registrarse y ver la discusión en la página de M-Vest. Para aquellos que no puedan asistir en vivo, una versión archivada de la presentación estará disponible en la sección 'Eventos y Presentaciones' del sitio web de Relaciones con Inversores de Zevra en investors.zevra.com.

Zevra Therapeutics (NASDAQ: ZVRA), 희귀 질환 치료를 전문으로 하는 회사는 2024 Maxim Healthcare Virtual Summit에서 희귀 질환 패널에 참여한다고 발표했습니다. 이 행사는 Maxim Group이 주최하며, 2024년 10월 17일 목요일, 오후 2시 ET에 예정되어 있습니다. Neil F. McFarlane Zevra의 사장 겸 CEO가 패널에서 회사를 대표할 것입니다.

회의는 M-Vest를 통해 생중계되며, 투자자들은 M-Vest 페이지를 통해 등록하고 토론을 시청할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 발표의 아카이브 버전은 Zevra 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션에서 investors.zevra.com에서 제공될 예정입니다.

Zevra Therapeutics (NASDAQ: ZVRA), une entreprise de thérapies pour les maladies rares, a annoncé sa participation à un Panel sur les Maladies Rares lors du 2024 Maxim Healthcare Virtual Summit. L'événement, présenté par Maxim Group, est prévu pour jeudi 17 octobre 2024, à 14h00 ET. Neil F. McFarlane, Président et CEO de Zevra, représentera l'entreprise lors du panel.

La conférence sera diffusée en direct sur M-Vest, avec possibilité pour les investisseurs de s'inscrire et de regarder la discussion via la page M-Vest. Pour ceux qui ne peuvent pas assister en direct, une version archivées de la présentation sera mise à disposition dans la section 'Événements & Présentations' du site web des Relations Investisseurs de Zevra à l'adresse investors.zevra.com.

Zevra Therapeutics (NASDAQ: ZVRA), ein Unternehmen für Therapien bei seltenen Krankheiten, hat seine Teilnahme an einem Panel für Seltene Krankheiten beim 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Die Veranstaltung, die von Maxim Group präsentiert wird, ist für Donnerstag, den 17. Oktober 2024, um 14:00 Uhr ET geplant. Neil F. McFarlane, Präsident und CEO von Zevra, wird das Unternehmen im Panel vertreten.

Die Konferenz wird live auf M-Vest übertragen, wobei Investoren sich registrieren und die Diskussion über die M-Vest-Seite verfolgen können. Für diejenigen, die nicht live teilnehmen können, wird eine archivierte Version der Präsentation im Abschnitt 'Veranstaltungen & Präsentationen' der Investor-Relations-Website von Zevra unter investors.zevra.com verfügbar sein.

Positive
  • None.
Negative
  • None.

CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET.

  • Maxim Group 2024 Annual Healthcare Conference Rare Disease Panel on Thursday, October 17, 2024, at 2:00 p.m. ET.

This conference will be live on M-Vest. To attend, investors can register and watch the company discussion on the M-Vest page. The archived presentation will also be accessible under “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com.

About Zevra:

Zevra Therapeutics is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.

Caution Concerning Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra’s Quarterly Report for the quarter ended June 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. 

Contacts: 

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Russo Partners Contacts:

David Schull
+1 (858) 717-2310
david.schull@russopartnersllc.com

Ignacio Guerrero-Ros, Ph.D.
+1 (646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com


FAQ

When is Zevra Therapeutics (ZVRA) participating in the 2024 Maxim Healthcare Virtual Summit?

Zevra Therapeutics (ZVRA) is participating in the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024, at 2 p.m. ET.

Who will represent Zevra Therapeutics (ZVRA) at the Rare Disease Panel?

Neil F. McFarlane, President and Chief Executive Officer of Zevra Therapeutics (ZVRA), will represent the company at the Rare Disease Panel.

How can investors watch Zevra Therapeutics' (ZVRA) presentation at the 2024 Maxim Healthcare Virtual Summit?

Investors can watch Zevra Therapeutics' (ZVRA) presentation by registering and viewing the live discussion on the M-Vest page.

Where can I find the archived presentation of Zevra Therapeutics (ZVRA) from the 2024 Maxim Healthcare Virtual Summit?

The archived presentation will be available in the 'Events & Presentations' section of Zevra Therapeutics' (ZVRA) Investor Relations website at investors.zevra.com.

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

ZVRA Rankings

ZVRA Latest News

ZVRA Stock Data

500.67M
49.84M
6.62%
54.57%
7.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CELEBRATION